Figure 11. Effect of metformin, nifedipine, MCC950, and anakinra treatment on Tet2-deficient myeloid blasts and BM cellularity.

(A) Representative flow cytometry profile of myeloid blasts (c-KIT⁺CD11b⁺ double-positive cells) in the PB of recipient mice after 30 days of drug treatment and quantification of c-KIT⁺CD11b⁺ double-positive cells in the PB, BM, and spleen. (B) BM cellularity after 30 days of the indicated drug treatment (n = 3–6 mice per group). Data are shown as the mean ± SEM. **P < 0.005, ***P < 0.0005, and ****P < 0.0001, by 1-way ANOVA.